![](https://investorshub.advfn.com/uicon/189332.png?cb=1465554763)
Tuesday, November 25, 2014 11:49:50 PM
Just to make a point about raising and trying to miss lead potential investors. What difference does it make as to who owns the plant?
Primarily - the implication is that IF Theracor/Dr. Diwan retain ownership of the plant then the plant is not an 'asset' for NNVC and is an asset for Dr. Diwan. This also makes rent/a lease a liability for NNVC if they do not own the plant.
There are pros and cons to owning the plant - some for tax purposes, others as to what the intrinsic book value of NNVC is (or could be). It is probably best in the medium term that NNVC owns the means of it's compounds' production - IMO. So that also is a benefit to NNVC owning it as opposed to Dr. Diawan.
Another of the innuendo's that has been tossed about is that the asking price for the plant IF NNVC buys it is that they will somehow 'overpay' Dr. Diawn and line his pockets more - at the expense of NNVC shareholders.
Since it appears from the 10Q and other filings that there is an auditor figuring out the cost before NNVC was to buy it back - this concern also appears to be trumped up and trivial. NNVC will not 'pay' more for the plant than it cost to build & refurbish as long as that auditor does its job.
So - ownership of the plant does have some significant consequences for NNVC. It's not some 'great conspiracy' or something though.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM